Results 221 to 230 of about 27,806,140 (362)

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

Science, 2018
V. Gopalakrishnan, C. Spencer, L. Nezi, A. Reuben, M. Andrews, T. Karpinets, P. Prieto, D. Vicente, K. Hoffman, S. Wei, Alexandria P. Cogdill, L. Zhao, C. Hudgens, D. Hutchinson, T. Manzo, M. Petaccia de Macedo, T. Cotechini, T. Kumar, W. Chen, S. Reddy, R. S. Szczepaniak Sloane, J. Galloway-Peña, H. Jiang, P. Chen, E. Shpall, K. Rezvani, A. Alousi, R. Chemaly, S. Shelburne, L. Vence, P. Okhuysen, V. B. Jensen, A. Swennes, F. McAllister, E. Marcelo Riquelme Sanchez, Y. Zhang, E. Le Chatelier, L. Zitvogel, N. Pons, J. Austin-Breneman, L. Haydu, E. Burton, J. Gardner, E. Sirmans, J. Hu, A. Lazar, T. Tsujikawa, A. Diab, H. Tawbi, I. Glitza, W. Hwu, S. Patel, S. Woodman, R. Amaria, M. Davies, J. Gershenwald, P. Hwu, J. Lee, J. Zhang, L. Coussens, Z. Cooper, P. Futreal, C. Daniel, N. Ajami, J. Petrosino, M. Tetzlaff, P. Sharma, J. Allison, R. Jenq, J. Wargo   +69 more
semanticscholar   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Monocyte HLA-DR expression in septic shock patients: insights from a 20-year real-world cohort of 1023 cases [PDF]

Guillaume Monneret, Thomas Lafon, Morgane Gossez, Bruno Evrard, Maxime Bodinier, Thomas Rimmelé, Laurent Argaud, Martin Cour, Arnaud Friggeri, Alain Lepape, Bernard Allaouchiche, Anne‐Claire Lukaszewicz, Fabienne Venet   +12 more
openalex   +1 more source

Successful bone marrow transplantation in a patient with DNA ligase IV deficiency and bone marrow failure [PDF]

, 2007
Bernd Gruhn, J. Seidel, F Zintl, Raymonda Varon, Holger Tönnies, Heidemarie Neitzel, Astrid Bechtold, Holger Hoehn, Detlev Schindler   +8 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Measuring Patient Satisfaction Changes Patient Satisfaction

Journal of Dermatological Treatment, 2012
Candace, Glenn, Amy, McMichael, Steven R, Feldman   +2 more
openaire   +3 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Hand-held dynamometry in patients with haematological malignancies: Measurement error in the clinical assessment of knee extension strength [PDF]

, 2009
Ruud H. Knols, Geert Aufdemkampe, Eling D. de Bruin, Daniel Uebelhart, Neil K. Aaronson   +4 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Anti-PLA2R antibody reduction as a predictor of treatment response in primary membranous nephropathy: a retrospective study. [PDF]

J Bras Nefrol
Bashir K, Asghar MR, Saleem N, Shahzil M, Riaz A, Hashmi MN, Sheraz A.   +6 more
europepmc   +1 more source